Allergy/Imm Medical News about chimeric antigen

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
Cancer Gene Therapy, 09/16/09

Li L et al. – The target–specific cytotoxicity for anti–CD19–BB–z mRNA–transfected NK cells was observed as early as 3 h after transfection and persisted for up to 3 days. The method described here should facilitate the clinical development of NK–based antigen–targeted immunotherapy for cancer.

Exclusive Author Commentary
L Li, 09/16/09

Concerns for safety, simplicity, scalability and cost become more and more important for both clinical study and the following commercialization of chimeric receptor technology. This translational study demonstrated the specific cytotoxic function of expanded and unstimulated resting NK cells toward specific target cells, like tumors, could be dramatically enhanced through mRNA non-viral gene modification with chimeric receptor by a GMP-compliant method, which is safe, efficient and cost effective. The method can be applied to chimeric receptors with different specificities, is demonstrated to be scalable, and should be easily translatable to clinical setting.

<< Previous
Follicular dendritic cell sarcoma with immature T-cell...

Next >>
Serum mucosa-associated epithelial chemokine in atopic dermatitis...